Drugs › Hyperpolarization-activated cyclic nucleotide-gated channel blocker
Generic name
Ivabradine: adverse event reports filed with FDA
1,766 reports list it as a suspect or interacting product, 2009–2026. Class: Hyperpolarization-activated cyclic nucleotide-gated channel blocker.
- 1,766
- reports as suspect product
- 0% of all reports · about 104 a year
- 148
- reports, 12 months to June 2026
- 202 in the 12 months before
- 90.1%
- marked serious by the reporter
- 56.9% across the class
- 11.7%
- record death among outcomes, as reported
- 206 reports · not verified by FDA
1,766 adverse event reports received by FDA list ivabradine, a generic name as a suspect or interacting product, from July 2009 to June 2026. A further 2,554 reports list it only as a concomitant medication, and those are not counted in the figures on this page.
In the 12 months to June 2026, 148 reports listed it, down 27% from 202 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 104 reports a year and 0% of the 20,646,523 reports in the database, and 48.9% of the reports for the hyperpolarization-activated cyclic nucleotide-gated channel blocker class. How many people take it is not in the data, so a count is not a rate of occurrence.
Reporters most often recorded off label use (14.9%), hypotension (11.7%) and bradycardia (11.5%). A report can list several reactions, so shares add to more than 100%; 472 different terms appear across these reports. Off label use is recorded in 14.9% of these reports, a smaller share than in the median hyperpolarization-activated cyclic nucleotide-gated channel blocker drug (32.6%).
90.1% of the reports are marked serious by the reporter (56.9% across the class); 11.7% record death among the outcomes and 45.5% record hospitalisation, as reported. 42.2% of the reports came from physicians, and the largest patient age group is 45 to 64 (28.4%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Ivabradine reports recording the termmedian drug in hyperpolarization-activated cyclic nucleotide-gated channel blocker
- Off label useused for a purpose or in a way not on the label14.9%263
- Hypotensionlow blood pressure11.7%206
- Bradycardiaslow heart rate11.5%203
- Drug interactionan interaction between medicines10.8%191
- Cardiac failureheart failure9.9%174
- Drug ineffectivethe medicine did not work as expected7.1%125
- Dyspnoeashortness of breath6.2%109
- Dizzinesslight-headedness or unsteadiness5.8%103
- Oedema peripheralswelling of the legs, ankles or hands5.1%90
- Syncopefainting4.4%78
- Chest painchest pain4.3%76
- Electrocardiogram QT prolongeda QT prolongation on the ECG4.3%76
- Palpitationsawareness of the heartbeat4.3%76
- Fatiguetiredness4.2%75
- Angina pectoris4%71
- Falla fall3.5%61
- Intentional overdosea deliberate overdose3.5%61
- Pulmonary oedemafluid in the lungs3.3%58
- Headachehead pain3.1%55
- Presyncope3%53
- Product use issuea problem in how the product was used2.9%52
- Torsade de pointesa serious irregular heart rhythm2.8%50
- Suicide attempta suicide attempt2.8%49
- Psoriasispsoriasis, a skin condition2.7%48
- Anaemialow red blood cells2.7%47
- Overdosea dose above the recommended amount2.7%47
- Contusiona bruise2.5%44
- Sinus bradycardia2.5%44
- Astheniaweakness or lack of energy2.4%43
Top 30 of 472 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 2 drugs in the hyperpolarization-activated cyclic nucleotide-gated channel blocker class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 3,611 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 19.3% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Cardiac failure | 123 | 7% |
| Cardiac failure chronic | 118 | 6.7% |
| Angina pectoris | 101 | 5.7% |
| Postural orthostatic tachycardia syndrome | 82 | 4.6% |
| Sinus tachycardia | 80 | 4.5% |
| Autonomic nervous system imbalance | 24 | 1.4% |
The indication field is filled in by the reporter and is often blank; shares are of all 1,766 reports.
Drugs most often listed in the same reports
| Drug (any role in the report) | Reports | Share of Ivabradine reports |
|---|---|---|
| Furosemide | 389 | 22% |
| Ramipril | 335 | 19% |
| Spironolactone | 297 | 16.8% |
| Bisoprolol | 246 | 13.9% |
| Carvedilol | 246 | 13.9% |
| Aspirin | 242 | 13.7% |
| Atorvastatin | 238 | 13.5% |
| Entresto | 147 | 8.3% |
| Metoprolol | 126 | 7.1% |
| Bisoprolol fumarate | 114 | 6.5% |
Other products listed in reports where Ivabradine is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.
In context
| Measure | Ivabradine | Hyperpolarization-activated cyclic nucleotide-gated channel blocker | All reports |
|---|---|---|---|
| Reports as suspect product | 1,766 | 3,611 | 20,646,523 |
| Share of that pool | — | 48.9% | 0% |
| Reports, latest 12 months | 148 | — | 1,332,454 |
| Marked serious | 90.1% | 56.9% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 117 | 71 | 91 |
| Hospitalisation recorded, per 1,000 reports | 455 | 266 | 213 |
| Consumer-filed share | 13% | 23.3% | 45.8% |
| Top term, share of reports | Off label use 14.9% | median 32.6% | 4.1% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Other drugs in the hyperpolarization-activated cyclic nucleotide-gated channel blocker class
| Drug | Name type | Reports | Latest 12 months | Marked serious |
|---|---|---|---|---|
| Corlanor | brand | 1,845 | 36 | 25.1% |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.
Questions about Ivabradine reports
How many adverse event reports has FDA received for Ivabradine?
1,766 reports list Ivabradine as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 148 of them arrived in the latest 12 months. Another 2,554 list it only as a concomitant medication.
What reactions are recorded in Ivabradine reports?
off label use (14.9%), hypotension (11.7%), bradycardia (11.5%), drug interaction (10.8%) and cardiac failure (9.9%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Ivabradine was responsible.
How serious are the reports?
90.1% are marked serious by the reporter. Among the outcomes recorded, 11.7% of reports include death and 45.5% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
physician (42.2%), other health professional (37.7%) and consumer or non-health professional (13%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Ivabradine rising?
148 reports in the 12 months to June 2026, down 27% from 202 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Ivabradine was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Ivabradine?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Ivabradine as a suspect or interacting product; reports listing it only as a concomitant medication (2,554) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.